194 related articles for article (PubMed ID: 36505833)
1. Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial.
Li G; Shu B; Zheng Z; Yin H; Zhang C; Xiao Y; Yang Y; Yan Z; Zhang X; Yang S; Li G; Dong J
Front Oncol; 2022; 12():1051916. PubMed ID: 36505833
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of the PD-1 Inhibitor Lenvatinib Plus Radiotherapy in Patients with HCC with Main PVTT: Real-World Data from a Tertiary Centre.
Li G; Zhao Y; Li K; Yang S; Xiang C; Song J; Yang Y; Li G; Dong J
J Hepatocell Carcinoma; 2023; 10():2037-2048. PubMed ID: 37965075
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
4. Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study.
Wang L; Wang H; Cui Y; Liu M; Jin K; Xu D; Wang K; Xing B
Front Oncol; 2023; 13():1115109. PubMed ID: 36874115
[TBL] [Abstract][Full Text] [Related]
5. Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study.
Zhu M; Liu Z; Chen S; Luo Z; Tu J; Qiao L; Wu J; Fan W; Peng Z
Hepatology; 2024 Feb; ():. PubMed ID: 38358542
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial.
Hu Y; Qin T; Li S; Zhang T; Xue J
Front Oncol; 2020; 10():1589. PubMed ID: 32984021
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol.
Wang K; Yu HM; Xiang YJ; Cheng YQ; Ni QZ; Guo WX; Shi J; Feng S; Zhai J; Cheng SQ
BMJ Open; 2022 Dec; 12(12):e064688. PubMed ID: 36521893
[TBL] [Abstract][Full Text] [Related]
9. Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis.
Zhang ZH; Hou SN; Yu JZ; Zhang W; Ma JQ; Yang MJ; Liu QX; Liu LX; Luo JJ; Qu XD; Yan ZP
Front Oncol; 2022; 12():1086095. PubMed ID: 36741718
[TBL] [Abstract][Full Text] [Related]
10. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study.
Li D; Xu L; Ji J; Bao D; Hu J; Qian Y; Zhou Y; Chen Z; Li D; Li X; Zhang X; Wang H; Yi C; Shi M; Pang Y; Liu S; Xu X
Front Immunol; 2022; 13():944062. PubMed ID: 36091003
[TBL] [Abstract][Full Text] [Related]
11. A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial).
Ichida A; Arita J; Hatano E; Eguchi S; Saiura A; Nagano H; Shindoh J; Hashimoto M; Takemura N; Taura K; Sakamoto Y; Takahashi Y; Seyama Y; Sasaki Y; Uemura K; Kokudo N; Hasegawa K
Liver Cancer; 2024 Jun; 13(3):322-334. PubMed ID: 38894811
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.
Sun L; Xu X; Meng F; Liu Q; Wang H; Li X; Li G; Chen F
Front Oncol; 2022; 12():980214. PubMed ID: 36249023
[TBL] [Abstract][Full Text] [Related]
13. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus.
Luo F; Li M; Ding J; Zheng S
Front Oncol; 2021; 11():635731. PubMed ID: 34631513
[TBL] [Abstract][Full Text] [Related]
14. Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: A case report.
Takahashi K; Kim J; Takahashi A; Hashimoto S; Doi M; Furuya K; Hashimoto R; Owada Y; Ogawa K; Ohara Y; Akashi Y; Hisakura K; Enomoto T; Shimomura O; Noguchi M; Oda T
World J Hepatol; 2021 Mar; 13(3):384-392. PubMed ID: 33815680
[TBL] [Abstract][Full Text] [Related]
15. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.
Hidaka Y; Tomita M; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
World J Surg Oncol; 2022 Jul; 20(1):228. PubMed ID: 35831894
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial.
Wei J; Lu X; Liu Q; Fu Y; Liu S; Li L; Liu F; Fan X; Yang J; Yang Y; Zhao Y; Guan W; Liu B
Cancer Manag Res; 2022; 14():2007-2015. PubMed ID: 35747712
[TBL] [Abstract][Full Text] [Related]
17. Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update.
Ye JZ; Wang YY; Bai T; Chen J; Xiang BD; Wu FX; Li LQ
Oncotarget; 2017 Nov; 8(54):93258-93278. PubMed ID: 29190996
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001).
Shang X; Zhao G; Liang F; Zhang C; Zhang W; Liu L; Li R; Duan X; Ma Z; Yue J; Chen C; Meng B; Ren X; Jiang H
Ann Transl Med; 2022 Feb; 10(4):229. PubMed ID: 35280363
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Yuan G; Cheng X; Li Q; Zang M; Huang W; Fan W; Wu T; Ruan J; Dai W; Yu W; Chen M; Guo Y; Hu X; Chen J
Onco Targets Ther; 2020; 13():12683-12693. PubMed ID: 33328740
[TBL] [Abstract][Full Text] [Related]
20. Triplet regimen as a novel modality for advanced unresectable hepatocellular carcinoma: A case report and review of literature.
Zhao Y; He GS; Li G
World J Clin Cases; 2023 Sep; 11(27):6558-6564. PubMed ID: 37900216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
